A detailed history of Cape Investment Advisory, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cape Investment Advisory, Inc. holds 42 shares of BMRN stock, worth $2,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42
Previous 178 76.4%
Holding current value
$2,799
Previous $15.5 Million 77.76%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $10,122 - $12,541
-136 Reduced 76.4%
42 $3.46 Million
Q4 2023

Feb 12, 2024

BUY
$76.22 - $98.51 $1,524 - $1,970
20 Added 12.66%
178 $17.2 Million
Q2 2023

Oct 12, 2023

BUY
$86.68 - $100.3 $4,767 - $5,516
55 Added 53.4%
158 $13.7 Million
Q1 2023

Oct 12, 2023

BUY
$87.74 - $117.27 $9,037 - $12,078
103 New
103 $10 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cape Investment Advisory, Inc. Portfolio

Follow Cape Investment Advisory, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cape Investment Advisory, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cape Investment Advisory, Inc. with notifications on news.